

Non-Executive Chairman Transition

Sydney, Australia – 17 May 2022: Cannabis focused drug development and product innovation company Bod Australia Limited (“Bod” or “the Company”) (ASX: BOD) wishes to advise that Mr Mark Masterson has resigned as Non-Executive Chairman, effective 16 May 2022 due to personal reasons. Recently appointed Non-Executive Director Mr David Baker will assume the role of Non-Executive Chairman.

Mr Masterson joined the Company’s Board in September 2019 and his guidance and expertise across the Company’s product development initiatives and clinical trial pipeline has been instrumental in Bod’s growth. The Company wishes him well for his future endeavours.

Recently appointed Non-Executive Director Mr David Baker will now assume the role of Non-Executive Chairman. Mr Baker joined the Company in April 2022 (refer ASX announcement: 4 April 2022). He is a commercial adviser and company director with over 40 years’ experience in law, investment banking, public company leadership and corporate governance. Mr Baker is also a longstanding shareholder in Bod.

The Company continues to assess additional director candidates to ensure it has adequate diversity and the necessary skill sets to advance its current clinical trial pipeline and product commercialisation initiatives.

Management commentary:

Non-Executive Chairman Mr David Baker said: *“Mark has provided exceptional guidance to Bod over the years and has been instrumental in the delivery of a number of the company’s major milestones. On behalf of the Board and management, I would like to thank him and wish him well for his future endeavours.*

“For my part, I look forward to working closely with the executive team and the Board to progress our current clinical trials, product development plans and execute potential licencing and partnership opportunities to drive revenue growth.”

This announcement has been approved by the Board of Bod Australia Limited.

-ENDS-

About Bod Australia:

Bod Australia Limited (ASX:BOD) Bod is a cannabis focused drug development and product innovation company.

Bod is focused on progressing R&D and a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for the consumer and medical markets.

The Company has a number of existing partnerships with large corporate groups and collaborations with leading research partners to advance the use of CBD.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538